Difference between revisions of "Obinutuzumab (GA101)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Replaced content with "Please see Obinutuzumab (Gazyva) page.")
Line 1: Line 1:
−
'''In clinical trials'''.  Also known as RO5072759, Afutuzumab.
+
Please see [[Obinutuzumab (Gazyva)]] page.
−
 
 
−
==General information==
 
−
Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody.  Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region, which is postulated to enhance its immunomodulatory effect.<ref>Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011 Jan-Feb;3(1):76-99. Epub 2011 Jan 1. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038014/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21051951 PubMed]</ref>
 
−
<br>Route: IV
 
−
<br>Extravasation: no information
 
−
 
 
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert.
 
−
 
 
−
==Diseases for which it is used==
 
−
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]
 
−
*[[Follicular lymphoma]]
 
−
 
 
−
==Patient drug information==
 
−
No information available.
 
−
 
 
−
==References==
 
−
<references/>
 

Revision as of 20:06, 17 December 2013

Please see Obinutuzumab (Gazyva) page.

Retrieved from "https://hemonc.org/w/index.php?title=Obinutuzumab_(GA101)&oldid=4138"